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Human papillomavirus type 11 (HPV-11), produced 
from the athymic mouse xenograft system, was 
shown to infect cultured neonatal human foreskin 
keratinocytes and the HaCaT keratinocyte cell line 
in vitro. Infection was documented by the appearance 
of HPV-11-specific spliced mRNA, detected by re-
verse transcriptase-polymerase chain reaction. Puri-
fied HPV-11 virions at concentrations of approxi-
mately 107 particles/ml could successfully evoke 
infection in this system. Infection was completely 
abrogated by preincubation of the HPV-11 inoculum 
with mouse anti-HPV -11 monoclonal antibodies, ex-
perimentally immunized animal sera, or sera of hu-
P api ll omaviruses arc w ide ly distributed, affect many spe -cies, and are important human pathogens that are etio logically associated with a spectrum of b enign and malignant epithelial conditions [1 ] . Until recently, there existed an in vestigational impasse for most types of 
human papillomavirus (HPV) because production of infectious vira l 
particles was not possib le. The d evelopment of th e a thymic mouse 
xenograft system h as a llowed substantial progress in the study of 
HPV-11 (2] . More recently, the discovery that HPV-li ke particles 
could be produced in e ukaryotic vectors has opened the way for 
further progress (3]. 
The detection and characterization of virus-ne utn1liz ing antibod-
ies are important fa cets of research aimed at understanding the 
immune system response to papillomavirus infection. Bovine pap-
illomavirus n e utralizing an tibodies have been detected using an 
i11 1itro focus-fo rming infectivity assay for b ovine papillomavirus 
with mouse fibrobla sts [ 4-6]. At present , animal mod els are use d 
for the detection of ne utrali zing antibodies for cottontail rabbit 
papillomavirus (CRPV) and HPV-11. CRPV-n e utralizing antibod-
ies have b een studied by their abi li ty to block papilloma formation 
in tl1e skin of CR.PV -inoculated rabbits [7 ,8]. T h e a thymic mouse 
xenograft system has been used to characterize antibodies capable 
of neutralizing CR..PV (9, 1 0] and HPV-11 infectivity [11, 12]. 
W e have been interested in the development of i11 11itro methods 
to facilitate study of HPV infectivity and neutralization. We have 
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man patients with HPV infection. Concurrent detec-
tion of cellular mRNA for the J3-actin gene, also by 
reverse transcriptase-polymerase chain reaction, 
provided an internal control confirming RNA recov-
ery and successful reverse transcriptase-polymerase 
chain reaction. Using this approach, it was possible to 
determine semiquantitative titers for test solutions of 
HPV-11-neutralizing antibodies. The i11 viti'O system 
for HPV-11 infectivity and neutralization may be 
useful in the study of the immune response to 
HPV-11 infection or immunization in patients. Key 
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previously reported evidence for infection b y HPV-11 of neonatal 
foreskin epithelial fragments cu ltured as explants i11 1itro [13]. H ere 
w e present data that de monstrate successful HPV-11 infection of 
c ultured human keratinocytcs and a keratinocyte cell line i11 virm. 
Th is i11. 11itro system can be u sed to characterize titers tor HPV-11 
infectivity and antibody-mediated neutra lization. 
MATEIUALS AND METHODS 
Production and Characterization of HPV -11 T he Hershey strain of 
1-IPV-11 was utilized to generate xcnograftcd condylon1a t issue in athyrnjc 
mice us in ~,; methods described previously ['\ 4]. Virus purification was as 
previously described with some modifi cations as follows. Condyloma tissue 
was combined with 3 volumes of buffer (0.02 M Tris. I M NaC I. pl-1 7.4) 
and ste rile washed sea sand (Fisher Scientific, Pittsburgh , PA), then ground 
into a thin slurry with a mortar and pestle . After removal of sand and tissue 
debris by low-speed centdfugation , virus particles were pelleted at 28.000 
rpm (Beckman Quick-seal polya llomer tubes, Beckman 70 .1 Ti rotor) for 
1 h at 4°C . T he pelle ts were then resuspended in buffer and overlayed onto 
discontinuous layers of cesium chloride solution as foll ows: bo ttom layer, 
2 ml CsCI, dcnsiry 1.5 g/ml; middle layer, 4 ml CsCI, dcnsiry 1.24 g/ ml; 
rcn1a.in.in g volunu~, virus suspensio n. After scd inlCilt&ltion at 28,000 rpm for 
1.5 h (Beckman 70. 1Ti rotor) at 4°C, virus bands were identified ncar the 
lower interf.,ce and co ll ected by bottom puncture of the tubes. Virus 
material was then dialyzed versus phosphate-buffered saline at 4°C . ali-
quoted. and then sto red at - 80°C . 
The vi rus preparation was characterized by 12% sodium dodecylsulfatc-
polyacrylamide ge l electrophoresis sta ined with Coolllassie brill.iant blue. As 
shown in Fig 1. thc preparation used in this work appeared to have a purity 
in excess of 90%. Bovine serum albumin (S igma , St. Louis, MO) was used 
&lS a quantitative standard. Fo llowing dcstaining, th e bovine scrun1 albu n1in 
and I-ll'V-1 ·1 L1 bands we re quantitated using a sc;mning densitometer with 
Gclscan XL software (l'harrnacia. Pi scataway, NJ). T he peak optica l density 
measurements of the BSA standards provided a linear curve from which the 
concentra tion of the 1-ll'V-ll L1 protein was measured by interpolation. A 
calculated H PV-11 particle concentration was derived given the n1 casurcd 
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Figure 1. Demonstration of HPV-11 purity and concentration. 
Analysis of bovine sentm albumin (BSA) standards and HPV-ll-purified 
virus to determine concentration and purity by 12% sodium dodecylsulfate-
polyacrylarnidc gel electrophoresis, stained with Coomassie bri!Hant blue. 
Lntte 1, HPV-11 virus preparation, 10 !L l ; ln11e 2, BSA, 0.125 !Lg; ln11e 3. BSA, 
0.250 !Lg; ln11e 4, BSA, 0.500 !Lg; la11c 5, BSA, 1.000 !Lg; ln11e 6, BSA, 2.000 
}.Lg; and ln11e 7. molecular weight standards. 
HPV-11 L1 concentration in the preparatio n, the known m olecular w eigh t 
of the L1 prote in , and an expected number of 360 L1 subuni ts per virion 
[15]. The HPV-11 virion concentratio ns g iven here are calculated concen-
trations based on prote in equiva lents of the L 1 prot:ein and do not re flect the 
possibility that some L1 pro tein may be presen t in empty or non-infec tious 
particles. T lus preparatio n was also characte rized by transmiss io n e lectron 
microscopy and contained in excess of 90'Yo co•nplctc viral particles (not 
shown). 
Neonatal Human Foreskin Keratinocyte Culture, HPV-11 Infec-
tion, and Neutralization Process ing of nconnral foreskin tissue '"'as as 
described previously [1 3] . The foreskin fragments were cultured (37"C. S'X. 
C02 ) on a feeder layer of m itomycin C-treatcd mouse 3T3 fibrob lasts 
[16,17) grown to 80'X• conAuency. Outgrowth keratinocytes we re cultured 
in Dulbecco's modified Eagle's medium containing fina l concentrations of 
the fo llowing: 10% fetal bovine serum , 10 ng/ml ep idermal growth fac tor, 
1 X 10- 11! M cholera toxin , 0.4 !Lglm l h ydrocortisone, 100 u / ml penicillin, 
100 j.Lg/ml streptomycin , and 0.25 /Lg/ ml amphotericin. Fresh m edium was 
adde d every other da y until day 7 w hen tissue fragments were removed and 
the medium was changed to a serum-free formulati o n containing 0.15 mM 
calcium (154/1-I.K.GS, Cascade Biolog ics, Po rtland , OR). After the out-
growth kerati nocytes had attained approximate!)' 50% conAuency, tllC)' 
wer e harvested by trypsinization (GIBCO-UR.L, Gaithersburg, MD) and 
cryopreserved. 
Conditions for the HPV-11 infectivity and neutra lizatio n studies utili zed 
cultured keratinocytes grown in 24-well tiss ue culture p lates (Corning, 
Corning, NY) . C ryoprcservcd second:~ ry kcratinocytcs were recovered and 
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seeded at I X I o·• ce lls/cm 2 and then grown to 50% conAucncy in 
154/ 1-!KGS medium . HaCaT ce ll s, an immorta lized human keratinocyte 
cell line !l SI (kindly provided by Dr. Norbert Fuscnig) , also grown in 
1 54/I-IKGS medium , were employed instead of cul tured secondary foreskin 
kcratinocytcs in sorn c cxpctin1cnts . At tltis titne , the n1cdia ·were asp irated 
and the cell s covered with approximately 500 ILl ofHPV-11 (filter sterili zed 
tltrough a 0.2 micro n low-protein b inding filter; Millipore, Bedford, MA) 
diluted as indica ted below in 154 / HKGS m edium. For antibody-mediated 
neutrali zation , appropriate dilutions of test antibody or serum were com-
bined w ith virus stock giving identical fin:1l virus concentrations , incubated 
for 1 ha t 37°C, then added to the cul tu.rcd kcratinocytes . Fresh mediLtm was 
added at 3 d . At 6 d the medium was removed and total cellular R.NA was 
harvested from each individual well using Tri Reagent (Molecular Research 
Center, Cinc inatti, 0 1-I) following the nl an u f.,cturer' s rcconuncndatio n s. 
Detection of Spliced HPV-11 and Cellular 13-Actin mRNAs by 
RT-PCR HPV-11 infection of cul tured human keratinocytes o r HaCaT 
cells after 6 d of culture was demonstrated by reverse transcriptasc-
po lymerase chain reaction (RT-PCR) to detect spliced HPV-11 mR.NA 
species utili z ing do no r/ acceptor nucleotides 847/3325 [1 3]. The location of 
primers used in th ese studies and their nucleotide sequences are shown in 
Table I . Although the use of30 PCR cycles had been previously employed 
to demonstrate sp li ced 1-I.PV-11 mR.NA from 1-I.PV-11-infected cultured 
foreskin tissue rragments [1.3], efficient and sensitive detection of HPV-1 ·1 
infection in this cell-cu lture system required use of nested PCR primer se ts 
and two 30-cycle PCR rounds. HPV-11 eD N A was primed with primer 
1-111 -DO as described previous ly (1 3). Follo"~ng eDNA S)~1tl1 esis primers 
1-1"11 -DO and 1-1 "1.1-UO were utili zed for 30 cycles of PCR (temperature 
profile: 94 °C / 30 seconds, 60°C / 30 seconds, 72°C/55 seconds with a final 
extension of72°C/10 min). A portion (5 !Ll oflOO 1.d) of the PCR reaction 
mi xtu re was then utilized for a second 30 cycles of PCR primed w ith 
primers H 11-UI and 1-1.11-DI using the same temperature profile. The fi nal 
amplirner size was 628 bp and this PCR product has been previously shown 
by nucleotide sequence analysis to o ri gin ate from HPV -11 mRNA utilizing 
the nucleo tid e 847 / 3325 donor/acceptor site [1 3). T he final concentration 
of deoxynucleotide triphosphates during e DNA synthesis and PCR was 0.2 
mM , except w here dUT P was uti li zed at 0.4 mM . Final concentration of 
p1·imcrs were 0.2 !LM in all cases. 
Fo r simultaneo us detec tio n of spli ced cellular {3-actin mR.N A. nested 
primers we re designed that overlapped sp lice donor/ acceptor sites (Los 
Alam os , GenBank) as shown in Table I . For eDNA syn thesis, primer 
BA-DO was added simultaneously with primer 1-1. "1 1-DO . Fo r tlte ftrSt 30 
cycles, primers BA-UO and BA-00 w ere u tilized simultaneously w ith 
primers 1-111-UO and 1-111-DO. For dt e second 30 cycles, primers BA-UI 
and 13A-DI were utilized simu ltaneously witl1 1-1.11-UI and 1-111-DI. Tern-
perature profi les were as shown above. T he final expected size of the PCR 
amplimer fo r 13-actin mR.NA was 429 bp. 
Carry-over conrmnin ation \Vas prevented by usc of a GencA_nlp Carry-
over prevention kit (Perkin Elmer) employing dUTP incorporation in to all 
PC R. rea cti o ns and destruction of contaminating amplimers using Amp 
Erase UNG, urac il N-glycosylase 11 9]. Usc of Amp Erase UNG glycosylase 
was acco rdin g to n1an ufitcturcr 's instruc tions in1rn ed i:ttcly prior to th e first 
30 cycles of PCR; the enzyme was inac tivated at 95°C fo r 10 min prior to 
initiatio n of PCR. All PC R data shown in this study. except th ose shown in 
Figs 2 and 3 , utilized the GeneAmp Carry-over preven tio n system. 
Contaminatio n events w ere a lso nunimizcd by usc ofbulk prepared so lu tion 
compo nents. dedicated laboratory equipmen t, and fi ltered pipe tte tips. 
Negative contro l PCR reactions were routinely performed, con fi rming the 
abse nce of co nran1ina tio n events. 
Table I. Reverse Transcriptase and Polymerase Chain Reaction Primers 
Prirner Loca tion in Nested Genomic Nucleotide Nucleotide Seq uence 
D escription Set Nurnbcrs" (5 '-->3 ' ) 
HPV-11 
HI1-UO Upstrcant , outside 765-787 ta caagaccttttgctgggcaca 
1-111-DO Downstream, o u ts ide 4088-4 I I 0 naaggc:lggaaaatagcacacac 
1-1.11-UI Upstrcan1, in side 792-8 12 ata ttgtgtgtcccatcrgcg 
1-111-DI Downstrean1 , inside 3877-3898 c:lgcaatttgtacaggcactac 
13-Actin 
BA-UO Upstream, outside "1578 -1 587 /2029 - 2039 gatgacccagatcatgtttg 
BA-DO Do,vnstrcanl, o utside 2735- 2744/2857-2867 ggagcaatgatcttgatcttc 
llA- Uf Upstrcant, in side 2046-2067 aacaccccagcca tgtacgttg 
BA-D I Downstrca n1, inside 2455-2467/2563-2570 actccatgctcaggaaggaagg 
a /, cxon-cxonjunction: DA-UO cxon 3-cxon 4 i BA-00 cxon 5- cxon 6: OA-01 cxon 4-cxon 5. 
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Figure 2. Nested PCR primers enhance detection of HPV-11 
spliced rnRNA. Eth idium-agarose gel electrophoresis of RT-PCR prod-
ucts from in 11itro infectivity assay with HPV-11. A) 30 rounds of PCR. 
amplification . B) 60 rounds of PCR ampli fication with nested primers. The 
following lanes contain RT-PCR. product derived from in lti/ro HPV-11 
infections using the following virus concentrations: lane ·t. 10- 2 dilution (3 
X 10 11 particle equivalcnts/ml); lane 2, 10- 3 dilution (3 X 10 111 particle 
equivalenrs/ml) ; lane 3, 10- 4 di lution (3 X 109 particle equi va lents/ml); lane 
4, 10- s dilution (3 X 1 0" particle equivalents/ml) ; lane 5, 10- 6 dilution (3 X 
107 particle equiva lents/ml); lmw 6, 10- 7 dilution (3 X 106 particle 
equivalcnts/ml) ; fan e 7, 1 0- H dilution (3 X 105 particle equivalents/ml) . 
Lane 8, positi ve control RNA from xenograft condyloma. 
The PC R. products were separated by agarose-ethidium gel electrophore-
sis and photographed using polaroid negative film (number 665, Polaroid 
Corp ., Cambridge, M.A) yield ing a negative image of the fluorescent bands 
that was processed by scanning densitometry. Densitometry was performed 
using a Helium-Neon laser scanner at 632.5 nm equipped with Gelscan XL 
software (Pharmacia, Piscataway, NJ). The relative amount of the HPV-11 
mR.NA PCR. amplimer (628 bp) and the cellular {3-actin mR.NA PCR. 
amplimer (429 bp) were determined by meas urement of the peak optical 
density (POD) of these bands. T he background optical density was deter-
mined by scanning appropriate regions of the film adjacent to the bands of 
interest, and was subtracted from the peak optical density of each band. A 
percent HPV-11 neutralization value was calculated as follows:% neutral-
ization = ·100 - [(normalized POON/normalized PODRcd X 100), where 
"normalized POD N" is the ratio of peak OD va!ul!S for the 628-bp and 
429-bp bands in a neutralization test, and "normalized POORer" is the ratio 
of peak 00 va lues for the 628-bp and 429-bp bands in a reference 
(unncutralized) test. Negative diff'ercnccs were given a va lue of zero. 
RESULTS 
We had previously employed 30 PCR cycles for detection of the 
628-bp PCR product d eriving from the spliced HPV-J 1 EJ "E4 
mRNA [1 3]. However, using cultured keratinocytes instead of 
tissue, the 2-m l w ell conditions described above w ith 6 d of cu lture, 
we found that 30 rounds of PCR resulted in poor sensitivi ty for 
detection of the spliced HPV-1 J mRNA. As illustrated in Fig 2, the 
use of nested primers and 60 tota l cycles of PCR has resulted in a 
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Figure 3. Iu rtitro RT-PCR assay demonstrated HPV-11 virus neu-
tralization by experimental sera. The fo llowing antibodies were used in 
the standard neutralization assay at the indicated concentrations. A) H1l.B2 
ascites (neutralizing): lane 1, 10- 2 dilution; lane 2. I 0- 3 dilution ; lane 3, 10- • 
dilution; lane 4, no antibody. B) H11 .H3 ti ssue culture supernatant (neu-
trali zing): lane 5, 1.0- 2 dilution; lane 6, I 0- 3 dilution; lau e 7, 10- • dilution; 
lane 8, no antibody. C) Rabbit anti-VLP 11-Ll: lane 9, 10- 2 dilution; lane 
10, 10- 3 dilution; lane 11, to- ·• dilution; lane '12, no antibody. D) 
Hyperimmune rabbit irrelevant antibody control: '"'"' 13, ·1 0- 2 dilution; lane 
14, 10- 3 dilution; lane 15, 1.0-'1 dilution; lane '16, no antibody. 1::.} Mouse 
anti-CR.PV ascites (CIU>V neutralizing/ HPV-11 nonncutralizing): lane 17, 
10- 2 dilution; lm.e 18, 10- 3 dilution; lone 19, 10- 4 dilution; lane 20, no 
antibody. F) Rabbit pre-immune: laue 21, 1 o- 2 dilution; lane 22, l 0- 3 
dilution; lane 23, 1 o-• dilution; lane 24 , no antibody. 
substantial increase in detection sensrt1v1ty. The HPV-11 virus 
stock was seria lly diluted to determine the lowest virus concentra-
t ion that could result in sp li ced HPV-11 n1.RNA detection under 
the conditio ns described here. Under these conditions , in 11itro 
HPV -11 infection can be detected down to a virus concentration of 
approximate ly 10 7 particles per milliliter (protein equivalents), 
corresponding to an initial multiplicity of 500 to 1000 viral particle 
equ iva lents per cell. 
Mouse monoclonal antibodies H1l.B2 and H11.H3 have been 
shown previously to neutralize the ability of HPV-11 to induce 
condylomata in the athymic mouse xenograft model (11] . These 
monoclonal antibodies were very active in neutralizing the ability 
of HPV-11 to induce the HPV-11-spliced mRNA in the in vitro 
system. As can be seen in Fig 3, both antibodies could be 
substan tially diluted and sti ll completely inhibit HPV -11 infection. 
Experimental antisera were al so tested for neutralizing activity in 
this i11 JJitro system. Figure 3 also shows the results with rabbit sera 
before and after in1mtmization against HPV-11 virus-like particles 
produced in a baculovirus vector [20]. The pre-immunization sera 
had no HPV-11-neutralizing activ ity . As previously reported [20] 
using the mouse xenograft HPV-11-neutralization assay, the post-
immunization serum was highly active and could in activate 
HPV-11 infection even at a dilution of 10 - 3 . 
/11 11itro titration of HPV -11 infectivity and antibody-mediated 
neutralization <~ppeared to be possible using the technique de-
scribed here. The reliabili ty of this method is affected by several 
sources of variab ility . HPV -11 virus preparations m<Iy vary in their 
content of infectious particles and therefore dilutional titration is 
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Figure 4. RT-PCR analysis demonstrates the effects of virus dilu-
tion, antibody neutralization and cell type . .R.T-PC R products sepa-
rated by aga rose-ethidium gel clcctro~ho rcsis. A mm1s mark positions of 628 
bp (HPV-Il mRNA) and 429 bp (/3-actin m.R.NA) ampumers. Ln11es 1-7 
show assays performed with cultured neonatal foreski n keratinocytes. Lntl<'.< 
1- 4 show results of unneutralized cultures using tenfold se rial dilutions of 
HPV-11 virus as fo llows: I nile 1, to-• dilution; lniiC 2, 1 o-s dilution; I nile 3 . 
10- 6 dilution; la11 e 4, 10- 7 dilution. Ln11cs 5-7 show results of assays 
performed with a 1:100 dilution ofHPV-11-neutra lizing mouse monoclo-
nal antibody H11 .B2 and HPV-11 virus dilutions as fo llows: ln11c 5, 1 o- ' 
dilution; lmze 6, 10- 4 dilution; ln11e 7,10- 5 dilution. Ln 11cs 8 -14 demonstrate 
results for similar assays as shown in ln11cs 1-7 except pcrfom1cd using the 
HaCaTccl lline. Lane 15 shows a contro l lane derived from R.NA extracted 
from HPV-11-induccd xenograft condyloma. Ln11e /6 shows <l>x174 DNA-
Hac 11.1 digest markers. 
required to choose the appropriate v irus dilution at w hi ch antibody-
mediated ne utralization can be observed consistently. Figure 4 
(lanes 5-7) shows the results ofHPV-11 n eutralization with a fi xed 
dilution of the HPV-11-neutraJizing m o use m onoclon al antibody 
H 11.B2. A lthough ne utraJizatio n was observed at t he 10 - 4 and 
10- 5 v irus dilutions, it was not observed at the 10- 3 dilution. A 
similar ca libration wou ld be required when using new o r previously 
untested HPV- 1 1 virus stocks in this assay. For the HPV-11 virus 
preparation described he re, a to- ·• dilution (approximately 1 o'' 
particle equivalen ts/m l) w as selected for neu trali zation studies 
u sing patient sera. 
Spurious absence of the 628-bp PCR product represen ting the 
spli.ced HPV-11 milNA could arise from loss of cel.lular RNA, 
failure of eD NA synthesis, or faulty PCR. To control for these 
potential sources of variability, an inte rnal control mRNA was 
needed that was expected to be presen t in all ce!Jular RNA extracts. 
T h e spliced {3- actin mRNA was chosen b ecause both genomic and 
eDNA sequences were available (Gen.Bank) an d because several 
exon-exon splice junctions [21] could be u tilized to derive specific 
p rimers for RT-PCR. DideOJo.:ysequence ana lys is of this amplimer 
fo llowing cloning into the p CR.2 vec tor, using previously described 
methods [13], demon strated the 429-bp {3-ac tin amplime r with an 
additionaJ 27 bp of flanking DNA located to the downstream side 
of primer BA-DI (Hitchcock, unpublished observation). T he 
source of this flanke r remains to be determined but all RT -PCR 
generated the same size amplimer for aU reaction s. W e refe r to this 
,13-actin amplimer as the 429-bp fra gment to reflec t the size of the 
,13-actin specific sequence. Figure 4 dem o nstrates that the appear-
ance of th e 429-bp RT -PC R product provided a clear marker for 
recovery of spliced {3-actin mRNA, confirmin g in th ose cases 
w here the 628-bp HPV-11 mRNA product was absent due to 
neutralization that the result was not due to loss of RNA or failure 
of RT-PC R . 
Routine cultivation of secondary cultures of neon ata l human 
fo reskin keratinocytes was also regarded as a source of variability 
for this work. T he source ofkeratinocytes for each preparation was 
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diffe rent and keratinocyte cultures som e times showed variable 
growth charac te risti cs. A continuous hum an ke ratinocyte cell line 
(HaCaT) was tested as a possible surrogate for cultured n eon ata l 
foreskin keratinocytes. Figure 4 (lanes 8-14) demonstrates th at 
HaCaT cell s can be substituted for neonatal human foreski n 
keratinocytes in both the infectivity titration and antib ody-medi-
ated n eutralization assays with nearly iden tical results . 
T he HPV-11 antibody-mediated neutra lization assay was used to 
screen for neutralizing activity within patien t sera. fn these studi es, 
conditio ns were adopted to optimize detection of neutralization as 
revealed by the data of Fig 4 (HaCaT cells were used and th e 
HPV-1 1 virus dilutio n was 1 o- •). The sera were screen ed in 
trip licate at a 1 :20 diJution, and single dete rminations were per-
formed at dilutions of1:40, 1:80, and 1:160. Sera from two patients 
w ith laryn geal p ap illo m atosis, four pati en ts with ongoing genita l 
condyloma , and four random blood donors were tested. The 
laryngeal papillomatosis patients (1-IMC-1 and HM C - 3) both had 
tissue typed as HPV 6/11 (Viratype) and both their sera had been 
shown to bind HPV-1 1 v i,;o ns by enzyme-linked immunosorben t 
assay and to n eutralize HPV-11 infectivity in the mouse xenograft 
assay f1 2]. Of the four condylom a patients, two (UCP-1 and 
U CP- 2) had been tissu e typed for HPV-11 u sing PCR with 
con sensus primers [22] . T issues from th e oth e r two condylo m a 
patients were un available for testing. M edical histories were not 
avai.lab le for the random blood donors. 
Figure 5 represents the resuJts of these assays on patient sera , 
showing the R T -PCR products separated by aga rose-ethid ium 
e lectrophoresis. T he presence of the 429-bp PCR amplimer result-
ing fro m the celJular {3- actin mRNA eliminated spurious loss of 
RNA or faiJure ofRT/ PCR. as an exp lanation for disappearance of 
the J-IPV-11 628 bp amplimcr in neu tra lized cul tures. Quanti tative 
d ata !Tom these gels, obtained by scannin g densitometry, is dis-
played in Table II. Four sera (HM C-1 . HMC-3 , UCP-l , and 
1U3D-4) had significant ne utraliz ing activity at the 1 :20 dilution ; 
two sera (HMC-3 and UCP-1) showed complete neutra.liza tion 
even at the 1:1 60 dilution. NT5 ., va lues (the most diluted seria l 
two-fold dilution capable of at least 50% neutraliza tion) differed 
dram atica lly between sera. 
T he median pe rcent n eutraliza tion values (at d1e 1:20 dilution) 
for sera with NT 5 0 vaJues less than 1:20 (UCP- 2, UCP- 3, UCP-4, 
lU3D-107 , IU3D-114, and RBD-115, each measured in triplicate) 
were signifi can tly different from the m edian pe rcent neutraJization 
valu es from sera w ith N T 5 0 values of 1:20 or g reater (HM C-1, 
HMC-3, U CP-1, and RBD-4 , also each in triplicate), using the 
Mann-Whitney test (p < 0.0001). Sera with N T 5 0 va lues of less 
than 1:20 (de tem1ined in triplicate) were regarded as non-neu tral-
izing. T hese data d em o nstrate that scanning densito m etry of th e 
R T -PC R. produ cts yie lds peak OD vaJues for t he 628-bp and 
429-bp bands tha t ar e reproducible, and that statisticaJ compari son 
of caJculated pe rcent u eutra.liza tio n va lues for different g roups of 
data is possible. 
DISCUSSION 
We have described an i11 11itro sys tem for detection and quan titation 
of 1-IPV -11 infectivity and antibody-mediated neu tralization. T his 
sys tem relies on R T-PCR detection of HPV-11- specific spliced 
mJl.NA as an indicator of successfu l infection. T he use ofRT-PCR. 
for de tection of HPV-11 infection ofxen ografi:ed foreskin tissue in 
tbe ath ym ic mouse h as b een described previously [23] . We h ave 
also reported successful use of this technique in de tec ting 1-IPV - 11 
infection of explanted foreskin epithe lium cultured i11 11itro [1 3]. 
l11 11itro infection by other papilJomaviruses has been described . 
BPV in fect ion of cultured mouse fibroblasts has been reported LS] 
and C RPV infection of a rabbit epidermal cell line h as aJso been 
o bserved f24] . HPV-1 infection of cul tured human epithelial ce ll s 
has been suggested by the presen ce of replicating DNA [25] or th e 
appearance of HPV-1-specifi c mR.NA (26,27). T he enhanced 
sen sitivi ty f01· de tecting I-IPV infection using R.T -PC R. techniq ues 
could provide a general too l for i11 1itro detection of other types of 
infectious HPV virions, pe rh;1ps even from clinical specimens. 
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T he i11 11itro m o del described here undoubtedl y re lics only on the 
initi a1 steps of HPV-11 infection for successful detection of infec-
tivity . Virus attachment, cel.l entry, tmcoating, translocation, and 
transcription arc probably required f01· success in this assay. It is 
unknown at this time exactly which of these steps may be inhibited 
by I-IPV-11-neutralizing antibodies. Roden cl nl [G] have shown 
that mouse monoclonal antibodies that can neutralize BPV infec-
tion of C127 fibroblasts act by at least two mechan.ism.s: those that 
inhibit cell binding and those that appear to block a subsequent step 
in the process of i11fection . There is no evidence that HPV DNA 
replication, late gene transcription, cellular differentiation, or virus 
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Figure 5. RT-PCR analysis of HPV-11 neutralization by patient 
sera. A) Ln11es 1-6, patient UCP-1 . La11cs "/-3, I :20 serum dilutions 
(tripli cate experiments): ln11 e 4, 1:40 dilution; ln11c 5, 1:80 dilution; ln11c 6, 
1:160 dilution. Lanes 7-12, R.BD-114 . Lanes 7-9, 1:20 se rum dilu tions 
(trip li cate experiments); ln11e 10, 1:40 dilution ; ln11e 1'1. 1:80 dilution; ln11e 12. 
1:160 dilution. Ln11es / 3-"18, IUJD-4. Lr11ws 13-15, 1:20 serum dilutions 
(tripli c"te experimems): ln11e 16 , I :40 dilution; '"'"'"/ 7. 1 :80 di lu tion; ln11e 18, 
1:160 di lu tion. Ln11es "/9-24, R.BD-115. Ln11cs 19-2 1, :1:20 serum dilution 
(tripli cate experiments); ln11e 22, 1 :40 dilution; ln11c 23 . 1 :80 dilution; ln~te 24, 
1:160 di lu tion . B) Lalli!.< "/-6, patient I-IMC-1. Ln11es "1-3, 1:20 semm 
dilutions (trip lic"te experiments); lrmc 4, 1: 40 d il ution; /a11e 5, 1:80 dilution ; 
lr11tc 6, 1: 160 dilution. Lflltlc< 7-12, paticllt 1-fMC-3. La11cs 7-9, 1:20 senm1 
dilutio ns (triplicate expe riments); ln11c "/ 0, 1 :40 dilu tion ; ln11e 11, 1:80 
dilution; ln11c 12. 1:160 dilution. Ln11es 13-1 8, patient UCP-3. Lnues 13-15. 
1:20 serum dilutions (trip li ca te experiments); ln11e 16, 1:40 dilution: la11c "/ 7, 
1:80 di lmion; ln11c 18, 1 :1.60 di lu tion. LatH'S "/ 9-24, patient UCP-2 . Ln11e.s 
19-2 1, 1:20 serum dilutions (triplicate experiments): ln11c 22, 1:40 dilution; 
lr11tc 23, 1:80 dilution: ln11 e 24, 1:160 dilution. C) Ln11es 1-6, patien t UCP-4. 
La11cs 1-3, 1:20 serum di lutions (tripli cate experiments); ln11c 4, 1:40 
dilution; lnue 5, I :80 dilution; lam: 6, 1: .160 di lu tion . Ln 11c 7, <l>,y174 DNA 
1-lAE Ill digest markers. La11cs 8- 13, IU3D-HJ7. La11cs 8 -1 0, 1:20 serum 
dilutions (triplic"te experiments); la11c "/1, 1:40 dilution; ln11e 12, 1:80 
di lu tion; lam: 13, 1:160 dilution . Lane 14, no sample. Ln11e 15. control from 
1-ll'V -11-induced xenograft cond yloma I"t.N A extra ct. Laue "/ 6, no sample. 
La11cs 17-19 derived from uninfected cultures (no virus contro ls). Ln11e 20, 
((>,y174 DNA Hac III digest marke rs. Lutes 2 1-23 derived from 1-IPV-11-
infectcd cu ltures without neutrali zing sera. La11cs 24 - 32. no sample. 
particle production occur in this i11 vitro cell-culture model. There-
fore, although this cell-culture model for HPV infection could be 
useful for studying the very early events of this process, it is 
unlikely, as now described, to provide a tool for study of the entire 
HPV life cycle. 
Iflater events in the HPV-ll infectious cycle are not occurring in 
the ilL vitro culture model described here, it is interesting that we 
consistently detect spliced HPV-11 mRNA, which utilizes splice 
donor/acceptor nucleotides 847/3325 often associated with tran-
scripts expressed during productive infection . Chow et nl [28] 
characterized I-IPV-11 mRNAs present in a mature genita1 condy-
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Table II. Calculation ofHPV-11 Neutralization Data Using Scanning Densitometry 
POD 
Serum Source Dilu tion II 628 bp 
HMC-1 1:20 3 0.06 ::+: 0.09" 
1:40 0.54 
1:80 0.61 
1:160 0.49 
HMC-3 I :20 3 0 ::+: 0 
"I :40 0 
1:80 0 
I :1 60 0 
UCP-1 1:20 3 0 ::+: 0 
1:40 0 
1:80 0 
I :160 0 
UCP- 2 1:20 3 0.40 ::+: 0.06 
1:40 0.6 1 
1:80 0.63 
1:160 0.54 
UCP-3 I :20 3 0.3 1 ::+: 0.03 
1:40 O.GS 
1:80 0.62 
I :160 0.64 
UCP-4 I :20 3 0.73 ::+: 0.04 
1:40 0.86 
1:80 0.85 
1:160 0.84 
RBD-4 I :20 3 0 ::+: 0 
I :40 0 
:1: 80 0 
1:160 0 
RBD-107 1:20 3 0.70 ::+: 0.02 
I :40 0.80 
UlU 0.8 1 
I :160 0.78 
RBD-11 4 I :20 3 0.57 ::+: 0.05 
I :40 0.62 
I :80 0.63 
I :1 60 0.52 
RBD-1 15 I :20 3 0.45 ::+: 0.03 
I :40 0.48 
1:80 0.43 
1:160 0.4 5 
a Mea n :!:: SO. 
b 1Yo NcuLrali zatio n: sec J\latcrials mul 1\rtctlwds. 
POD 
429 bp 
0.49 ::+: 0.05" 
0.45 
().50 
0.48 
0.38 ::+: 0.1 0 
0.5 1 
0.45 
0.49 
0.44 ::+: 0.01 
0.45 
0.37 
0.45 
0.4 1 ::+: 0.03 
0.37 
0.35 
0.4 1 
0.27 ::+: O.J 3 
0.37 
0.43 
0.34 
0.46 .::+: 0.02 
0.58 
0.56 
0.53 
0.30 ::+: 0.04 
0.3 1 
0.28 
0.24 
0.42 ::+: 0.03 
0.48 
0.53 
0.43 
0.4 1 .::+: 0.01 
0.38 
0.38 
0.3 1 
0.25 ::+: 0.03 
0.1 8 
0. 13 
0. 12 
1X1 Ncu tT;~ Ii zation 
::+: so" 
89 ::+: 20 
0 
0 
0 
100 .::+: 0 
100 
t OO 
100 
100 ::+: 0 
100 
.100 
100 
38 ::+: 10 
0 
0 
0 
33 ::+: 30 
0 
0 
0 
3 .::+: 5 
0 
0 
0 
100 ::+: 0 
100 
100 
45 
4 ::+: 3 
0 
0 
0 
19 ::+: 20 
0 
0 
0 
47 ::+: 6 
23 
0 
0 
NT so~ 
I :20 
> 1:160 
> 1:"1 60 
< 1:20 
< 1:20 
< 1:20 
1:80 
< "1: 20 
< 1:20 
< "1 :20 
r NTsu• ne utra lization titer (hig ltcsc rwofold serial dil uti o n resulti ng in ar lc:ts t 501% Hcufrali z at:ion). 
lorna fi nding the predominant species to be HPV-11 E1 A£4 mR.N A 
utilizin g the nuc leotide 84 7/3325 spl ice. Stole r ct a/ [29) found that 
transcription fi~om the E4- ES open reading fram e dramatically 
increased in difFe rentiating cells within xenograft condyloma. H ow-
ever, C how el nl [26] studied HPV-l mRN A recovered from 
HPV-1-infectcd cultured ke ra tinocytes finding the m ost abundant 
ml~A species to be an El AE4 transcript. Althoug h exp ressed 
more inten sely as cellular difFerentiation occurs, it is possible that 
th e HPV-11 E 1 A£4 mR.NA appears in a subset of infected nondif-
ferentiating kcratinocytes c ul tured i11 11ilro. Furthe r characterization 
of the HPY-1 1 spliced mRNA de tected in the ce ll culture system 
described he re w ill be the goal of future studies. 
A pplica tion of the i11 11itro assay described here for m easurem e n t 
of HPY-11 ne u trali z ing an tibodies fi·om patient se ra o r secre tions is 
feasible. A two- step process of scrceni11g samples at a fixed dilutio n 
fo llowed by a more detailed t itra tio n of specimens with ne u tra li z ing 
activity resul ts in e fl'icient characterizatio n o f patient se ra . The 
cJ.i.njcal relevance oHindi11g HPV-11-neu trali zing antibodies and of 
hjgh o r low N T 5 0 va lues in patients w ith HPV-11 infectio ns o r in 
no rmal con tro ls re m ains to be explored. T h e i11 tJitro method for 
H PV -11-nc u tr ali z i.ng an ti body determination has several advan-
tages compared to th e origin al m o use xenograft m eth od (14]. 
Substan tial sav ings in time and effort arc possible; no expcrim cma l 
anima ls arc used and titrations of ne utrali z ing activity arc possible. 
T he use of a cloned and well-characte rized ce ll line (HaCaT) 
provides the opportuni ty fo r othe r laboratories to employ tlus assay 
unde r standardized conditio ns, limitin g va riability du e to no n-
unifo rm primary keratinocytc culture charactet·isti cs. T he i11 tlilro 
m odel for HPV-11 in fectivity and neutra liza tion sho uld fa cilita te 
further immunologic studies o n the response to HPV-11 infec tion 
and inununiza tion . 
11flc /ll is!t to tlumk Dr. J ames Cnrlso 11 for pmJJidiug labomtoq' .facilitit~s aud H abib 
Tmji _{i,r tl'rl111 iral nssisttwrc. Tit is 1110rk was suppoi1etl iu pm1 by n .<!l"fl tlf .from the 
Hil>bnrd E. J,lliflinllls, M.D. R<:sl"tll"l"h Fuud. 
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